Equity Profile
Pre-Earnings Brief
Royalty Pharma PLC Class A is a healthcare company focused on acquiring and managing revenue-generating pharmaceutical royalties. With a market cap of $22 billion, it plays a significant role in the pharmaceutical industry by providing funding to drug developers while sharing in the success of their products.
EPS
Earnings per share is a key indicator of the company's profitability and is closely watched by investors.
Revenue
Total revenue reflects the company's ability to generate sales from its royalty agreements, which is crucial for growth.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
13%
Avg EPS Surprise
+5.28%
Avg Stock Reaction
+0.00%
In the previous quarter, Royalty Pharma reported an EPS of -$0.04, continuing a trend of losses. Revenue figures were not disclosed, making it difficult to assess performance.
Management Promises & Guidance
Analysts expect Royalty Pharma to report a slight profit this quarter, with EPS projected at $1.18 and revenue at $874 million. The market is looking for signs of recovery after several quarters of losses.
Bull Case
If Royalty Pharma meets or exceeds the EPS and revenue estimates, it could signal a turnaround in profitability, boosting investor confidence.
Bear Case
Conversely, if the company fails to meet these expectations, it may raise concerns about its business model and ability to generate sustainable revenue.
EPS
$1.18Earnings per share is a key indicator of the company's profitability and is closely watched by investors.
Revenue
$874MTotal revenue reflects the company's ability to generate sales from its royalty agreements, which is crucial for growth.
Expectations
The print will turn on these two things.
Q1
Will the EPS meet or exceed the consensus estimate of $1.18?
This number is crucial for assessing the company's profitability and could significantly influence investor sentiment.
Q2
What is the revenue figure relative to the consensus of $874 million?
Revenue performance will indicate the effectiveness of Royalty Pharma's royalty agreements and overall business health.
Edge
Why consensus could be wrong
The Street may underestimate the potential for Royalty Pharma to achieve profitability this quarter, given the recent trends in the pharmaceutical sector.
Supporting Evidence
The company has a strong portfolio of royalty agreements that could yield better-than-expected results.
Options pricing suggests a higher volatility expectation, indicating that traders may foresee significant movements.
Key Risk
If the EPS comes in significantly above $1.18, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a series of losses, and investors are eager to see if the company can turn things around.
Bull Confirmed If
Achieving an EPS of $1.18 or higher would confirm a positive outlook for the company.
Bear Confirmed If
An EPS below $1.17 would raise concerns about the company's financial health.
Pre-Earnings Positioning
Implied Move
±10.2%
The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.
ATM IV
0.5%
30d HV
21.5%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.2% (modestly positive historical bias).
Edge
Smart-money positioning from the most recent 13F filings.
Institutional
84.49%
of float
Insider
7.12%
of float
Holders
844
institutions
Top Holders· as of Dec 2025
Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%
Capital International Investors
31,104,309 sh · $1.5B
7.00%
14.3%
FMR, LLC
26,272,308 sh · $1.3B
5.91%
-6.1%
Blackrock Inc.
26,188,692 sh · $1.3B
5.89%
-0.1%
BAILLIE GIFFORD & CO
17,008,768 sh · $839.9M
3.83%
-2.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Royalty Pharma beats expectations, history suggests a potential average 1-day move of +5.8%, confirming a positive trend.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss could lead to a significant drop, with historical patterns suggesting a potential average decline of around 5.8%.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AXSOME THERAPEUTICS